Ella is owned by Lab Hra Pharma.

Ella contains Ulipristal Acetate.

Ella has a total of 8 drug patents out of which 0 drug patents have expired.

Ella was authorised for market use on 13 August, 2010.

Ella is available in tablet;oral dosage forms.

Ella can be used as method for providing post coital contraception to a woman by administering about 30 mg of ulipristal acetate within about 120 hours after intercourse, wherein the woman is overweight having a bmi of 25 to 29.99, a method for contraception, the method comprising administering a tablet comprising 20 mg to 30 mg of ulipristal acetate to a woman within 120 hours after an unprotected intercourse, a method for contraception comprising the step of oral administration a dosage of 20 mg to 30 mg of ulipristal acetate to a woman within 72 hours and up to 120 hours after an unprotected intercourse, method for contraception to a woman comprising administering to the woman 30mg of ulipristal acetate more than 72 hours and up to 120 hours after an unprotected intercourse, ella is a progesterone agonist/antagonist emergency contraception indicated for the prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella can be taken with or without food.

Drug patent challenges can be filed against Ella from 13 August, 2014.

The generics of Ella are possible to be released after 12 June, 2030.